Methods and compositions based on ALK1 antagonists for modulating angiogenesis and pericyte coverage

Details for Australian Patent Application No. 2009241755 (hide)

Owner Acceleron Pharma, Inc. Ludwig Institute for Cancer Research Ltd.

Inventors Pietras, Kristian; Knopf, John; Grinberg, Asya; Pearsall, Robert Scott; Kumar, Ravindra; Seehra, Jasbir

Agent Davies Collison Cave

Pub. Number AU-A-2009241755

PCT Pub. Number WO2009/134428

Priority 61/144,131 12.01.09 US; 61/050,168 02.05.08 US

Filing date 1 May 2009

Wipo publication date 5 November 2009

International Classifications

A61P 35/00 (2006.01) Antineoplastic agents

A61P 37/00 (2006.01) Drugs for immunological or allergic disorders

C07K 14/71 (2006.01) Peptides having more than 20 amino acids

C07K 16/18 (2006.01) Immunoglobulins, e.g. monoclonal or polyclonal antibodies - against material from animals or humans

Event Publications

16 December 2010 PCT application entered the National Phase

  PCT publication WO2009/134428 Priority application(s): WO2009/134428

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2009241759-Data collection and targeted advertising systems and methods

2009241750-Touch sensitive video signal display for a programmable multimedia controller